• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clarification of the relationship between Helicobacter pylori flora and related diseases

Research Project

Project/Area Number 15K08952
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Gastroenterology
Research InstitutionKochi University

Principal Investigator

Mizuta Hiroshi  高知大学, 教育研究部医療学系臨床医学部門, 助教 (70527605)

Co-Investigator(Kenkyū-buntansha) 竹内 啓晃  高知大学, 教育研究部医療学系臨床医学部門, 講師 (90346560)
小野 正文  高知大学, 教育研究部医療学系臨床医学部門, 准教授 (70304681)
西原 利治  高知大学, 教育研究部医療学系臨床医学部門, 教授 (60145125)
Research Collaborator YANO Yukari  高知大学, 医学部附属病院, 医員
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Keywordsヘリコバクターピロリ / 遺伝子多様性 / ピロリ菌フローラ / 耐性菌 / 多様性 / ヘリコバクター・ピロリ
Outline of Final Research Achievements

Helicobacter pylori (HP) is characterized by the great genetic diversity. However, the drug susceptibility test is usually performed for only 1 strain per patient in clinical practice. We performed biopsies from the corpus and antrum of the stomach in all patients, cultured HP, and identified 6 strains at each part (total of 12 strains per patient). The sensitivity of HP to four antimicrobial drugs was examined.
We found bacterial susceptibility to antimicrobial drugs differed among the strains colonized in the same patients. Therefore, it is difficult to discuss drug resistance by the verification of only one strain from individual patient. Regarding to effective eradication therapy, it is important to know the great diversity of drug-susceptibility among individual HP strains in the stomach.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • Research Products

    (5 results)

All 2017 2016

All Presentation (5 results) (of which Int'l Joint Research: 2 results)

  • [Presentation] Vonoprazan-based third-line triple therapy in Helicobacter pyloli eradication and study of the diversity of antimicrobial susceptibilities.2017

    • Author(s)
      Yukari Yano
    • Organizer
      APDW 2017
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] ボノプラザンを用いたH.Pylori三次除菌療法について2017

    • Author(s)
      津田 尚子
    • Organizer
      第23回日本ヘリコバクター学会学術集会
    • Related Report
      2017 Annual Research Report
  • [Presentation] 同一患者内におけるH.Pyloriの薬剤感受性の多様性について2017

    • Author(s)
      矢野 有佳里
    • Organizer
      第23回日本ヘリコバクター学会学術集会
    • Related Report
      2017 Annual Research Report
  • [Presentation] P-CABを用いたH.pylori三次除菌療法と菌多様性を考慮した薬剤感受性の検討2016

    • Author(s)
      矢野有佳里,水田洋,北川達也,羽柴基,吉良瑞喜,岡本宣人,竹内啓晃,小野正文,西原利治
    • Organizer
      第58回日本消化器病学会大会(JDDW)
    • Place of Presentation
      神戸コンベンションセンター(兵庫県神戸市)
    • Year and Date
      2016-11-03
    • Related Report
      2016 Research-status Report
  • [Presentation] POTASSIUM-COMPETITIVE ACID BLOCKER-BASED THIRD-LINE TRIPLE THERAPY IN HELICOBACTER PY-LORI ERADICATION AND STUDY OF THE DIVERSITY OF ANTIMICROBIAL SUSCEPTIBILITIES.2016

    • Author(s)
      Yano Y,Mizuta H,Kira M,Matsumura Y,Kitagawa T,Hashiba M,Okamoto N,Takeuchi H,Ono M,Saibara T
    • Organizer
      24th United European Gastroenterology Week
    • Place of Presentation
      Austria Vienna
    • Year and Date
      2016-10-15
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi